Jan 27, 2020 09:23 PM IST
The biologics segment grew 50 percent year-on-year (YoY) in nine-month period to Rs 1594 crores, led primarily by contributions from Pegfilgrastim and Trastuzumab in US market.
- Jan 27, 2020 10:27 AM IST
Inspection of the Bengaluru facility took place between January 20 and January 24, 2020,
- Jan 24, 2020 01:30 PM IST
- Jan 23, 2020 08:56 PM IST
Revenues rose YoY 14 percent to Rs 1784 crore in the third quarter.
- Jan 20, 2020 10:45 AM IST
The US Food and Drug Administration (USFDA) conducted a pre-approval inspection of the oral solid dosage manufacturing facility of Biocon Pharma, a subsidiary of Biocon, which was triggered by the submission of an abbreviated new drug application, the company said in a regulatory filing.
- Jan 07, 2020 01:30 PM IST
"We might raise little more private equity prior to IPO. This basically gives an idea of where we believe we can unlock the value in terms of Biocon Biologics in the next few years," she said.
- Jan 07, 2020 08:46 AM IST
Chinappa joins Biocon Biologics from another subsidiary company Syngene International, where he was President (Finance) and CFO since 2008
- Jan 06, 2020 04:16 PM IST
Biocon said it would use the proceeds of stake sale for expansion of R&D and manufacturing capabilities.
- Jan 02, 2020 10:17 PM IST
The company has set an ambitious target of clocking $1 billion in sales by FY22 through its biologics division, which is at near fourfold jump in terms of sales from FY19.
- Dec 13, 2019 08:11 AM IST
Trends on SGX Nifty indicate a positive opening for the broader index in India, with a 30 points gain. Nifty futures were trading around 12,050 levels on the Singaporean Exchange
- Dec 12, 2019 07:02 PM IST
Equillium had secured exclusive rights to develop and commercialize Biocon’s novel biologic, itolizumab, for the U.S. and Canada markets, in May 2017
- Dec 03, 2019 02:45 PM IST
Morgan Stanley has an overweight call on the stock, with a target price at Rs 350 per share.
- Dec 03, 2019 09:42 AM IST
Research house Citi has maintained buy rating on Biocon with a target at Rs 350 per share.
- Dec 03, 2019 08:13 AM IST
Trends on SGX Nifty indicate a negative opening for the broader index in India with a 17.5 points loss. Nifty futures were trading around 12,074-levels on the Singaporean Exchange
- Dec 02, 2019 07:50 PM IST
Shaw, who had earlier said the government treated India Inc as "pariahs" and doesn't want to hear any criticism of the economy, was responding to Finance Minister Nirmala Sitharman remarks that spreading one's own impression "can hurt national interest" in relation to the statement made by Bajaj on Saturday.
- Dec 02, 2019 06:42 PM IST
Ogivri was the first biosimilar of Herceptin to be approved by USFDA two years ago, for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer.
- Nov 27, 2019 09:46 AM IST
"This is a significant milepost in our journey of serving 5 million patients by FY22 and crossing a revenue milestone of $1 billion," said Christiane Hamacher, CEO, Biocon Biologics.
- Nov 22, 2019 06:32 PM IST
The Biocon chief also flagged the deepening trust deficit between government and the industry saying there is an increasing tendency to criminalise every businessman.
- Nov 06, 2019 10:44 AM IST
The market has done well during recent times, caution may be required in the short-term, say experts.
- Nov 05, 2019 10:39 AM IST
The company had undergone good manufacturing norms compliance inspection of the unit from August 22-30, Biocon said in a regulatory filing.
- Oct 28, 2019 05:40 PM IST
It continues to be the only company from Asia to feature on the prestigious US-based 'Science' magazine's annual 'Science Careers Top 20 Employers' list, since its debut in 2012.
- Oct 24, 2019 08:14 AM IST
Trends on SGX Nifty indicate a positive opening for the broader index in India, with a 27.5 points gain or 0.24 percent. Nifty futures were trading around 11,666-level on the Singaporean Exchange.
- Oct 23, 2019 08:40 PM IST
Consolidated total income of the company stood at Rs 1,610.6 crore for the quarter under consideration as against Rs 1,375.4 crore for the same period year ago.
- Sep 20, 2019 08:26 PM IST
The company is confident of addressing these observations effectively through a Corrective and Preventive Action (CAPA) plan, expeditiously, it added.
- Sep 12, 2019 08:05 PM IST
Biocon will be responsible for the development, manufacturing and supply of the products while CMS will be responsible for registration and commercialisation of the products in China.